This protocol is judged by an institutional evaluate board, an unbiased team that reviews any clinical trials involving people. If a review consists of a Schedule I drug, as soon as the board approves the protocol as moral, the researchers need to apply for an investigational new drug (IND) variety in the FDA.Luckily, other providers with practical